This will kick the GLP-1RA revolution in a new gear.
it’s already one of the most common drug classes in the US and not having to inject and falling prices (see Novo Nodirsk’s subscription model) will help with access.
I think being able to use a pill instead of an injection will be a huge shift for many people. This will be further accelerated by Medicare offering Foundayo for $50 copay for eligible patients.